Carrillo ER, Herrera GJC, Carrillo CLD

Language: Spanish
References: 30
Page: 80-86
PDF size: 131.13 Kb.

ABSTRACT

Massive hemoptysis has multifactorial etiology and high morbimortality. The treatment of this pathology must be early and timely and includes airway control, support measures and hemorrhage control based on fibrobroncoscopy, laser photocoagulation, arterial embolization and surgery. Recombinant activated VII factor (rFVIIa) is a novel therapeutic approach for acute critical bleeding in hemophilic and non hemophilic patients. There are lots of publications concerning its efectivity in hemorrhage secondary to thrombocytopenia, thrombocytopathy, trauma, hepatopathy, hepatic transplantation, oral anticoagulant intoxication, postcardiac surgery bleeding, etc., but worldwide there are not reports for its use in massive hemoptysis. The objective of this paper is to describe the rFVIIa use in a patient with massive hemoptysis secondary to bronquiectasia treated in the intensive care unit of the Clinic Foundation Medica Sur and to review the literature.

REFERENCES

1. González GC. Hemoptisis. En: Medina Asensio J. ed. Manual de urgencias médicas. 2ª ed. Hospital “12 de Octubre”. Madrid, Díaz de Santos S.A. 1997: 165-170.

2. Hirshberg B. Hemoptysis etiology and evaluation and outcome in a tertiary referral hospital. Chest 1997; 112: 440-4.

3. Baptiste JH, Barcells JA, Villanau MA. Clinical assessment and management of massive hemoptysis. Crit Care Med 2000; 28: 1642-47.

4. Fein AE, Haponik EA, Jacob LI, Bidwell ME, Pachner RW. Managing lifethreatening hemoptysis, has anything really changed? Chest 2000; 118: 1431-1435.

5. Dweik RA, Martinowitz JE. Role of broncoscopy in massive hemoptysis. Clin Chest Med 1999; 20: 89-105.

6. Enomoto TE, Per Thorborg JE. Emerging Off-label uses for recombinant activated factor VII: Grading the evidence. Crit Care Clin 2005: 611-632.

7. Marcel LE, Marjolein PE, Büller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: A systematic review. Crit Care Med 2005; 33: 883–890.

8. Chacón MM, González CO, Vega ZR, García LS, Arias SEA. Factor VII activado recombinante: una opción en el manejo de la hemorragia grave. Rev Asoc Mex Med Crit y Ter Int 2004; 18: 207-214.

9. James A, Macdonald MB et al. Successful use of recombinant factor VII in massive hemoptysis due to community-acquired pneumonia. Chest 2006; 130: 5-15.

10. Uhlmann EJ, Eby CS. Recombinant activated factor VII for non-hemophiliac bleeding patients. Curr Opin Hematol 2004; 11: 198–204.

11. White B, Martin M, Kelleher S et al. Successful use of recombinant FVIIa (Novoseven) in the management of pulmonary haemorrhage secondary to Aspergillus infection in a patient with leukemia and acquired factor VII deficiency. Br J Haematol 1999; 106: 254–255.

12. De Graff W, Daenen S et al. Successful treatment of massive hemoptysis in acute leukemia with recombinant factor VIIa. Arch Intern Med 2000; 160: 2216–2217.

13. Hicks K, Peng D, Gajewski JL. Treatment of diffuse alveolar hemorrhage after allogenic bone marrow transplant with recombinant factor VIIa. Bone Marrow Transplant 2002; 30: 975–978.

14. Hedner U. Recombinant factor VIIa (Novoseven) as a hemostatic agent. Dis Mon 2003; 49: 39–48.

15. Martinowitz U. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 2005; 3: 640-8.

16. Carrillo-Esper R, Elizondo-Argueta S, Sánchez-Zúniga MJ, Carrillo-Córdova JR. Hemorragia alveolar secundaria a lupus eritematoso generalizado, tratada con factor VII recombinante activado. Informe de un caso y revisión de la literatura. Gac Méd Méx 2007; 143(1): 83-86.

17. Knott-Craig CJ, Oostuizen JG, Rossouw G, Joubert JR, Barnard PM. Management and prognosis of massive hemoptysis. Recent experience with 120 patients. J Thorac Cardiovasc Surg 1993; 105: 394-7.

18. Cahill BC, Ingbar DH. Massive Hemoptysis. Assessment and management. Clin Chest Med 1994; 15: 147-67.

19. Reisz G, Stevens D, Boutwell C, Nair V. The causes of hemoptysis revisited. A review of the etiologies of hemoptysis between 1986 and 1995. Mo Med 1997; 94: 633-5.

20. Hirshberg B, Biran I, Gkazer M, Kramer MR. Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. Chest 1997; 112: 440-4.

21. Carrillo ER, Salmeron NP, Carvajal RR, Contreras DV, Hernández AC. Rompiendo el paradigma del modelo humoral al modelo celular de coagulación. Aplicación clínica en el enfermo grave. Rev Asoc Mex Med Crit Ter Int 2004; 18: 17-23.

22. Enomoto MT, Thorborg P. Emerging off- label uses for recombinant activated factor VII: Grading the evidence. Crit Care Clin 2005; 21: 611-632.

23. Hoffman M, Monroe III MD. The action of high-dose factor VIIa in a cellbased model hemostasis. Disease-a-Month 2003; 49: 1-7.

24. Veldman A, Hoffman M, Ehrenforth S. New Insights into the Coagulation System and Implication for New Therapeutic Options recombinant Factor VIIa. Curr Med Chem 2003; 10: 797-811.

25. Lisman T, De Groot PG. Mechanism of action of recombinant activated Factor VII. TATM 2003; 5: 5-20.

26. Jean-Louis V, Rossaint R, Riou B, Ozier Y, Zideman D, Spahn DR. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding-a European perspective. Crit Care 2006; 10: 1-12.

27. Betensley AD, Yankansas JR. Factor VIIa for alveolar hemorrhage in microscopic polyangiitis. Am J Respir Crit Care Med 2002; 166: 1291-1292.

28. Santos-Ocampo AS, Mandell BF, Fessler BJ. Alveolar hemorrhage in systemic lupus erythematosus: presentation and management. Chest 2000; 118: 1083-1090.

29. Collard HR, Schwarz MI. Diffuse alveolar hemorrhage. Crit Care Clin 2004; 18: 583-592.

30. Primack SL, Miller RR, Müller NL. Diffuse pulmonary hemorrhage: clinical, pathologic, and imaging features. Am J Roentgenol 1995; 164: 292-300.